Sensitivity of Diagnostic and Localization Tests for Pheochromocytoma in Clinical Practice
Ronald M. Witteles, BA;
Edwin L. Kaplan, MD;
Michael F. Roizen, MD
Arch Intern Med. 2000;160:2521-2524.
Background Although pheochromocytomas are believed to account for fewer than 0.3% of all cases of hypertension, aggressive diagnostic and surgical intervention is recommended whenever a pheochromocytoma is suspected because uncontrolled catecholamine release from the tumors can lead to catastrophic consequences. Many biochemical diagnostic and imaging localization tests exist for detecting pheochromocytomas. We sought to evaluate the sensitivity of these tests used over a 35-year period at a single institution.
Methods Thirty-five patients with complete medical records who had pathologically confirmed pheochromocytomas between 1962 and 1997 at the University of Chicago Hospitals were identified. Sensitivity and 95% confidence intervals were calculated for 12 laboratory diagnostic tests and 5 imaging studies.
Results The most sensitive laboratory diagnostic tests in our study were plasma total catecholamines (95%) and urine total metanephrines (100%). Testing for urine vanillylmandelic acid, while less expensive and easier to perform than many other tests, had a slightly lower sensitivity (89%). The most sensitive imaging tests in the study were magnetic resonance imaging (100%) and iodine I-131 metaiodobenzylguanidine scintigraphy (100%). The more often used computed tomography had only 88% sensitivity. Localization was safely and successfully performed on two pregnant patients using magnetic resonance imaging and ultrasound.
Conclusions By properly choosing from the wide array of laboratory diagnostic and imaging tests, pheochromocytomas can be identified and localized with nearly 100% sensitivity. These tests should be performed in any patient for whom the diagnosis of pheochromocytoma is being considered.
From the Departments of Anesthesia and Critical Care (Mr Witteles and Dr Roizen), Medicine (Mr Witteles and Dr Roizen), and Surgery (Dr Kaplan), University of Chicago Hospitals, Chicago, Ill.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pheochromocytoma: an update on genetics and management
Karagiannis et al.
Endocr Relat Cancer 2007;14:935-956.
ABSTRACT
| FULL TEXT
Scintigraphic Imaging of Body Neuroendocrine Tumors
Intenzo et al.
RadioGraphics 2007;27:1355-1369.
ABSTRACT
| FULL TEXT
Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma
Lam et al.
J. Clin. Endocrinol. Metab. 2005;90:5888-5895.
ABSTRACT
| FULL TEXT
Comparison of CT Findings in Symptomatic and Incidentally Discovered Pheochromocytomas
Motta-Ramirez et al.
Am. J. Roentgenol. 2005;185:684-688.
ABSTRACT
| FULL TEXT
Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma
Ilias and Pacak
J. Clin. Endocrinol. Metab. 2004;89:479-491.
FULL TEXT
Undiagnosed Pheochromocytoma: The Anesthesiologist Nightmare
Myklejord
Clin Med Res 2004;2:59-62.
ABSTRACT
| FULL TEXT
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders et al.
JAMA 2002;287:1427-1434.
ABSTRACT
| FULL TEXT
State-of-the-Art Adrenal Imaging
Mayo-Smith et al.
RadioGraphics 2001;21:995-1012.
ABSTRACT
| FULL TEXT
Drug points: Pseudophaeochromocytoma syndrome associated with clozapine
Krentz et al.
BMJ 2001;322:1213-1213.
FULL TEXT
|
